GLP T was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.

GLPR is a powerful triple agonist peptide that targets GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors—making it the most comprehensive metabolic peptide in its class. It builds on the progress of earlier compounds like other GLP peptides, by activating three key hormonal pathways involved in appetite regulation, glucose control, and fat metabolism.

This enhanced activity leads to faster, more dramatic fat loss while offering additional therapeutic effects across multiple body systems.